IPO Year: 2021
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/9/2025 | Buy → Neutral | BTIG Research | |
| 1/13/2025 | $4.00 | Equal Weight → Underweight | Barclays |
| 12/20/2024 | $5.00 | Equal-Weight | Stephens |
| 9/17/2024 | $7.00 | Buy | BTIG Research |
| 7/31/2024 | $7.00 → $5.00 | Neutral → Underweight | JP Morgan |
| 5/8/2024 | $11.50 → $9.00 | Overweight → Equal-Weight | Morgan Stanley |
| 1/17/2024 | Buy → Hold | Needham | |
| 1/5/2024 | Buy → Hold | Canaccord Genuity | |
| 7/24/2023 | $13.00 | Outperform → Neutral | Robert W. Baird |
| 4/19/2023 | Outperform | William Blair |
4 - Definitive Healthcare Corp. (0001861795) (Issuer)
4 - Definitive Healthcare Corp. (0001861795) (Issuer)
4 - Definitive Healthcare Corp. (0001861795) (Issuer)
4 - Definitive Healthcare Corp. (0001861795) (Issuer)
4 - Definitive Healthcare Corp. (0001861795) (Issuer)
4 - Definitive Healthcare Corp. (0001861795) (Issuer)
4 - Definitive Healthcare Corp. (0001861795) (Issuer)
4 - Definitive Healthcare Corp. (0001861795) (Issuer)
4 - Definitive Healthcare Corp. (0001861795) (Issuer)
4 - Definitive Healthcare Corp. (0001861795) (Issuer)
FRAMINGHAM, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare" or the "Company") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended March 31, 2025. First Quarter 2025 Financial Highlights: Revenue was $59.2 million, a decrease of 7% from $63.5 million in Q1 2024. Net Loss, inclusive of goodwill impairment charges of $176.5 million, was $(155.1) million, or (262)% of revenue, compared to $(12.7) million or (20)% of revenue in Q1 2024. Adjusted Net Income was $7.0 million, compared to $13.0 million in Q1 2024. Adjusted EBITDA was $14.7 million, or 25% of revenue, compar
FRAMINGHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that it will report financial results for its first quarter ended March 31, 2025, on Thursday, May 8, 2025 after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company's financial results. A live audio webcast of the event will be available on the Definitive Healthcare's Investor Relations website at https://ir.definitivehc.com/. A live dial-in will be available at 877-358-7298 (domestic) or +1-848-488-9244 (international). Shortly
FRAMINGHAM, Mass., April 04, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that in connection with the hiring of one senior leader, the Human Capital Management and Compensation Committee (the "Committee") of Definitive Healthcare's Board of Directors granted inducement awards. The Committee granted Jeff Moyer, Definitive Healthcare's new SVP of Growth and Sales Operations, an inducement award consisting of 364,432 time-based restricted stock units ("RSUs"), effective April 3, 2025. These awards were individually negotiated and granted as an inducement material to Mr. Moyer's respective commencement of
FRAMINGHAM, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that in connection with the hiring of two senior leaders, the Human Capital Management and Compensation Committee (the "Committee") of Definitive Healthcare's Board of Directors granted inducement awards. The Committee granted Kate Hastings, Definitive Healthcare's new Chief Customer Officer an inducement award consisting of 172,414 time-based restricted stock units ("RSUs") effective March 3, 2025 and granted Benjamin Graboske, Definitive Healthcare's new EVP, Technology, Engineering and Chief Data Officer an inducement award co
FRAMINGHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare" or the "Company") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights: Revenue was $62.3 million, a decrease of 6% from $65.9 million in Q4 2023. Net Loss, inclusive of goodwill impairment charges of $97.1 million, was $(84.7) million, or (136)% of revenue, compared to $(13.4) million or (20)% of revenue in Q4 2023. Adjusted Net Income was $12.6 million, compared to $10.6 million in Q4 2023. Adjusted EBITDA was $17.5 million, or 28%
FRAMINGHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that its Chief Executive Officer, Kevin Coop, and its Chief Financial Officer, Rick Booth, will present at the Raymond James 2025 Institutional Investors Conference. The Definitive Healthcare presentation is scheduled for Tuesday, March 4, 2025, at 3:25 p.m. Eastern Time. A live webcast of the presentation will be available on the Events page of the Definitive Healthcare investor relations website at https://ir.definitivehc.com/. A replay of the webcast will also be available for a limited time. A
FRAMINGHAM, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that it will report financial results for its fourth quarter and full year ended December 31, 2024, on Thursday, February 27, 2025 after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company's financial results. A live audio webcast of the event will be available on the Definitive Healthcare's Investor Relations website at https://ir.definitivehc.com/. A live dial-in will be available at 877-358-7298 (domestic) or +1-848-488-9244 (i
FRAMINGHAM, Mass., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that it has been named one of Built In's 100 Best Places to Work in Boston, MA for 2025. The annual awards program includes companies of all sizes, from startups to large enterprises, and honors both remote-first employers as well as companies in large tech markets across the U.S. "We are honored to once again be recognized as a best place to work," said Kevin Coop, Chief Executive Officer at Definitive Healthcare. "People join Definitive Healthcare to make an impact in healthcare and the culture we have reflects that shared sen
FRAMINGHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that its Chief Executive Officer, Kevin Coop, and its Chief Financial Officer, Rick Booth, will present at the 27th Annual Needham Growth Conference. The Definitive Healthcare presentation is scheduled for Wednesday, January 15, 2025, at 2:15 p.m. Eastern Time. About Definitive HealthcareAt Definitive Healthcare, our mission is to transform data, analytics, and expertise into healthcare commercial intelligence. We help clients uncover the right markets, opportunities, and people, so they can shape
FRAMINGHAM, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare" or the "Company") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights: Revenue was $62.7 million, a decrease of 4% from $65.3 million in Q3 2023. Net Loss, inclusive of goodwill impairment charges of $228.2 million, was $(187.8) million, or (300%) of revenue, down 24% compared to $(248.7) million, inclusive of goodwill impairment charges of $287.4 million, or (381%) of revenue in Q3 2023.Adjusted Ne
BTIG Research downgraded Definitive Healthcare from Buy to Neutral
Barclays downgraded Definitive Healthcare from Equal Weight to Underweight and set a new price target of $4.00
Stephens initiated coverage of Definitive Healthcare with a rating of Equal-Weight and set a new price target of $5.00
BTIG Research initiated coverage of Definitive Healthcare with a rating of Buy and set a new price target of $7.00
JP Morgan downgraded Definitive Healthcare from Neutral to Underweight and set a new price target of $5.00 from $7.00 previously
Morgan Stanley downgraded Definitive Healthcare from Overweight to Equal-Weight and set a new price target of $9.00 from $11.50 previously
Needham downgraded Definitive Healthcare from Buy to Hold
Canaccord Genuity downgraded Definitive Healthcare from Buy to Hold
Robert W. Baird downgraded Definitive Healthcare from Outperform to Neutral and set a new price target of $13.00
William Blair initiated coverage of Definitive Healthcare with a rating of Outperform
SC 13G - Definitive Healthcare Corp. (0001861795) (Subject)
SC 13G - Definitive Healthcare Corp. (0001861795) (Subject)
SC 13G/A - Definitive Healthcare Corp. (0001861795) (Subject)
SC 13G/A - Definitive Healthcare Corp. (0001861795) (Subject)
SC 13G/A - Definitive Healthcare Corp. (0001861795) (Subject)
SC 13G/A - Definitive Healthcare Corp. (0001861795) (Subject)
SC 13G - Definitive Healthcare Corp. (0001861795) (Subject)
SC 13G/A - Definitive Healthcare Corp. (0001861795) (Subject)
SC 13G/A - Definitive Healthcare Corp. (0001861795) (Subject)
SC 13G - Definitive Healthcare Corp. (0001861795) (Subject)
SCHEDULE 13G/A - Definitive Healthcare Corp. (0001861795) (Subject)
SCHEDULE 13G - Definitive Healthcare Corp. (0001861795) (Subject)
10-Q - Definitive Healthcare Corp. (0001861795) (Filer)
8-K - Definitive Healthcare Corp. (0001861795) (Filer)
DEFA14A - Definitive Healthcare Corp. (0001861795) (Filer)
DEF 14A - Definitive Healthcare Corp. (0001861795) (Filer)
S-8 - Definitive Healthcare Corp. (0001861795) (Filer)
10-K - Definitive Healthcare Corp. (0001861795) (Filer)
8-K - Definitive Healthcare Corp. (0001861795) (Filer)
SCHEDULE 13G/A - Definitive Healthcare Corp. (0001861795) (Subject)
FRAMINGHAM, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare" or the "Company") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended March 31, 2025. First Quarter 2025 Financial Highlights: Revenue was $59.2 million, a decrease of 7% from $63.5 million in Q1 2024. Net Loss, inclusive of goodwill impairment charges of $176.5 million, was $(155.1) million, or (262)% of revenue, compared to $(12.7) million or (20)% of revenue in Q1 2024. Adjusted Net Income was $7.0 million, compared to $13.0 million in Q1 2024. Adjusted EBITDA was $14.7 million, or 25% of revenue, compar
FRAMINGHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that it will report financial results for its first quarter ended March 31, 2025, on Thursday, May 8, 2025 after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company's financial results. A live audio webcast of the event will be available on the Definitive Healthcare's Investor Relations website at https://ir.definitivehc.com/. A live dial-in will be available at 877-358-7298 (domestic) or +1-848-488-9244 (international). Shortly
FRAMINGHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare" or the "Company") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights: Revenue was $62.3 million, a decrease of 6% from $65.9 million in Q4 2023. Net Loss, inclusive of goodwill impairment charges of $97.1 million, was $(84.7) million, or (136)% of revenue, compared to $(13.4) million or (20)% of revenue in Q4 2023. Adjusted Net Income was $12.6 million, compared to $10.6 million in Q4 2023. Adjusted EBITDA was $17.5 million, or 28%
FRAMINGHAM, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that it will report financial results for its fourth quarter and full year ended December 31, 2024, on Thursday, February 27, 2025 after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company's financial results. A live audio webcast of the event will be available on the Definitive Healthcare's Investor Relations website at https://ir.definitivehc.com/. A live dial-in will be available at 877-358-7298 (domestic) or +1-848-488-9244 (i
FRAMINGHAM, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare" or the "Company") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights: Revenue was $62.7 million, a decrease of 4% from $65.3 million in Q3 2023. Net Loss, inclusive of goodwill impairment charges of $228.2 million, was $(187.8) million, or (300%) of revenue, down 24% compared to $(248.7) million, inclusive of goodwill impairment charges of $287.4 million, or (381%) of revenue in Q3 2023.Adjusted Ne
FRAMINGHAM, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that it will report financial results for its third quarter ended September 30, 2024, on Thursday, November 7, 2024 after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company's financial results. A live audio webcast of the event will be available on the Definitive Healthcare's Investor Relations website at https://ir.definitivehc.com/. A live dial-in will be available at 877-358-7298 (domestic) or +1-848-488-9244 (international).
FRAMINGHAM, Mass., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare" or the "Company") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended June 30, 2024. Second Quarter 2024 Financial Highlights: Revenue was $63.7 million, an increase of 5% from $61.0 million in Q2 2023. Net Loss, inclusive of goodwill impairment charges of $363.6 million, was $(306.2) million, or (480%) of revenue, up 2,538% compared to $(11.6) million, or (19%) of revenue in Q2 2023. Adjusted Net Income was $14.2 million, compared to $12.4 million in Q2 2023. Adjusted EBITDA was $20.9 million, up 21% from
FRAMINGHAM, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that it will report financial results for its second quarter ended June 30, 2024, on Monday, August 5, 2024 after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company's financial results. A live audio webcast of the event will be available on the Definitive Healthcare's Investor Relations website at https://ir.definitivehc.com/. A live dial-in will be available at 877-358-7298 (domestic) or +1-848-488-9244 (international). Shortly
FRAMINGHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare" or the "Company") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended March 31, 2024. First Quarter 2024 Financial Highlights: Revenue was $63.5 million, an increase of 7% from $59.2 million in Q1 2023. Net Loss was $(12.7) million, or (20%) of revenue, compared to $(16.0) million, or (27%) of revenue in Q1 2023. Adjusted Net Income was $13.0 million, compared to $9.1 million in Q1 2023. Adjusted EBITDA was $20.0 million, or 32% of revenue, compared to $15.7 million, or 26% of revenue in Q1 2023. Cash Flow
FRAMINGHAM, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that it will report financial results for its first quarter ended March 31, 2024, on Tuesday, May 7, 2024 after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company's financial results. A live audio webcast of the event will be available on the Definitive Healthcare's Investor Relations website at https://ir.definitivehc.com/. A live dial-in will be available at 877-358-7298 (domestic) or +1-848-488-9244 (international). Shortly a
FRAMINGHAM, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that its Board of Directors has appointed Kevin Coop as the Company's next Chief Executive Officer and as a member of the Board of Directors, each effective June 24, 2024. Mr. Coop succeeds Jason Krantz, founder and Executive Chairman, who has been serving as Interim CEO since January 2024. Mr. Krantz will continue to serve on the Board of Directors as Executive Chairman after the CEO transition. "Kevin is an outstanding leader. He has deep, hands-on experience with data-focused businesses and has a
Jim Emling, the CEO of Datassential and former long-time president of Milwaukee-based Zywave, has been appointed Executive Chair of the Board of Directors at VBA, the company announced today. "We are delighted to welcome Jim officially to VBA as the Executive Chair," said Michael Clayton, the company's President and CEO. "Jim and I have worked closely together over the last 3 months and his decades of experience scaling high growth software companies combined with his strong ties to the Milwaukee technology sector will be tremendous assets to VBA as we enter our next phase of growth." Emling has deep roots in the Milwaukee technology community. He was the founding CTO of Zywave and serv
FRAMINGHAM, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that Carrie Lazorchak has been named Chief Revenue Officer, effective November 1, 2023. "I am thrilled to welcome Carrie Lazorchak to Definitive Healthcare as our new Chief Revenue Officer," said Robert Musslewhite, Chief Executive Officer of Definitive Healthcare. "Carrie is a fantastic fit for Definitive Healthcare. Her values and her deep belief in the power of humble collaboration make her a perfect match for our culture. Carrie brings a wealth of experience selling Software as a Service to both enterprise accounts and